Abstract
Background: Patients with severe coronavirus disease 2019 (COVID-19) develop a febrile pro-inflammatory cytokinemia with accelerated progression to acute respiratory distress syndrome (ARDS). Here we report the results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of intravenous (IV) plasma-purified alpha-1 antitrypsin (AAT) for moderate to severe ARDS secondary to COVID-19 (EudraCT 2020-001391-15).
Methods: Patients (n = 36) were randomized to receive weekly placebo, weekly AAT (Prolastin, Grifols, S.A.; 120 mg/kg), or AAT once followed by weekly placebo. The primary endpoint was the change in plasma interleukin (IL)-6 concentration at 1 week. In addition to assessing safety and tolerability, changes in plasma levels of IL-1β, IL-8, IL-10, and soluble tumor necrosis factor receptor 1 (sTNFR1) and clinical outcomes were assessed as secondary endpoints.
Findings: Treatment with IV AAT resulted in decreased inflammation and was safe and well tolerated. The study met its primary endpoint, with decreased circulating IL-6 concentrations at 1 week in the treatment group. This was in contrast to the placebo group, where IL-6 was increased. Similarly, plasma sTNFR1 was substantially decreased in the treatment group while remaining unchanged in patients receiving placebo. IV AAT did not definitively reduce levels of IL-1β, IL-8, and IL-10. No difference in mortality or ventilator-free days was observed between groups, although a trend toward decreased time on ventilator was observed in AAT-treated patients.
Conclusions: In patients with COVID-19 and moderate to severe ARDS, treatment with IV AAT was safe, feasible, and biochemically efficacious. The data support progression to a phase 3 trial and prompt further investigation of AAT as an anti-inflammatory therapeutic.
Funding: ECSA-2020-009; Elaine Galwey Research Bursary.
Keywords: COVID-19; acute respiratory distress syndrome; alpha-1 antitrypsin; clinical trial; coronavirus; cytokines; inflammation; interleukin-6; randomized control trial.
【저자키워드】 COVID-19, Inflammation, coronavirus, clinical trial, Cytokines, acute respiratory distress syndrome, interleukin-6, alpha-1 antitrypsin, randomized control trial, randomized control trial., 【초록키워드】 Treatment, Necrosis, ARDS, Mortality, Trial, Anti-inflammatory, IL-6, progression, Clinical outcome, Randomized, placebo-controlled trial, phase 3 trial, therapeutic, IL-8, plasma, Placebo, receptor, multicenter, IL-10, moderate, patients, acute respiratory distress, IL-1β, Concentration, primary endpoint, Safe, double-blind, intravenous, Support, Tolerability, ventilator, Secondary endpoints, severe coronavirus disease, severe ARDS, syndrome, treatment group, EudraCT, circulating, febrile, pro-inflammatory, Grifols, develop, addition, changes in, biochemically, reduce, feasible, groups, accelerated, receive, patients receiving placebo, patients with COVID-19, the placebo group, ventilator-free day, was increased, were assessed, 【제목키워드】 ARDS, Randomized, placebo-controlled trial, double-blind, intravenous,